View source for Isoxsuprine sandbox

{{DrugProjectFormSinglePage
|authorTag={{SS}}
|genericName=Isoxsuprine 
|aOrAn=a
|indication=cerebral vascular insufficiency, peripheral vascular disease of [[arteriosclerosis obliterans]], [[thromboangitis obliterans]] ([[Buerger's Disease]]) and [[Raynaud's disease]].
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=<u>Cerebral Vascular Insufficiency</u>

* Dosing information
:* '''10 to 20 mg PO tid or qid'''

<h4>Peripheral Vascular Disease</h4>

* Dosing information
:* '''10 to 20 mg PO tid or qid'''
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine  in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine  in adult patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine  in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine  in pediatric patients.
|contraindications=There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.
|warnings=FDA Package Insert for Isoxsuprine contains no information regarding Warning.
|clinicalTrials=On rare occasions oral administration of the drug has been associated in time with the occurrences of [[hypotension]], [[tachycardia]], [[nausea]], [[vomiting]], [[dizziness]], abdominal distress, and severe [[rash]].  If rash appears the drug should be discontinued.
Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused.
|administration=Oral
|monitoring=FDA Package Insert for Isoxsuprine contains no information regarding drug monitoring.
|IVCompat=There is limited information about the IV Compatility.
|overdose=FDA Package Insert for Isoxsuprine contains no information regarding Adverse Reactions.
|drugBox={{chembox2
| Verifiedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = R15UI3245N
| verifiedrevid = 444643797
|ImageFile=Isoxsuprine.png
|ImageSize=150px
|IUPACName=4-{1-hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol
|OtherNames=Vasodilian, Duvadilan
|Reference=<ref>[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3783 Isoxsuprine - Compound Summary], [[PubChem]].</ref>
|Section1={{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3651
| InChI = 1/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3
| InChIKey = BMUKKTUHUDJSNZ-UHFFFAOYAW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BMUKKTUHUDJSNZ-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=395-28-8
| PubChem=3783
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1197051
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08092
| SMILES = O(c1ccccc1)CC(NC(C)C(O)c2ccc(O)cc2)C
| MeSHName=Isoxsuprine
| ATCCode_prefix = C04
| ATCCode_suffix = AA01
  }}
|Section2={{Chembox Properties
| C = 18 | H=23|N=1|O=3
|  MolarMass=301.38012
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}
|mechAction=FDA Package Insert for Isoxsuprine contains no information regarding mechanism of action.
|structure=lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter
taste, It has a following structural formula

[[File:lsoxsuprine_structure_01.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
|PD=FDA Package Insert for Isoxsuprine contains no information regarding pharmacodynamics.
|PK=FDA Package Insert for Isoxsuprine contains no information regarding pharmacokinetics.
|nonClinToxic=FDA Package Insert for Isoxsuprine contains no information regarding nonclinical toxicology.
|clinicalStudies=FDA Package Insert for Isoxsuprine contains no information regarding clinical studies.
|howSupplied=lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's
|alcohol=Alcohol-Isoxsuprine  interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
}}
{{PillImage
|fileName=No_image.jpg
|drugName=Isoxsuprine Hydrochloride 20 MG Oral Tablet
|NDC=61971-065
|drugAuthor=Vista Pharmaceuticals, Inc
|ingredients=lactose, cellulose, microcrystalline, calcium phosphate, dibasic, anhydrous, povidone k30, sodium starch glycolate type a potato, magnesium stearate
|pillImprint=20;VISTA065
|dosageValue=20
|dosageUnit=mg
|pillColor=White
|pillShape=Round
|pillSize=10.00
|pillScore=2
}}
{{LabelImage
|fileName=Isoxsuprine_label_01.jpg
}}
{{LabelImage
|fileName=Isoxsuprine_panel_01.png
}}